secwatch.observer — SEC 8-K summary
======================================

Issuer:     AEON Biopharma, Inc. (AEON)
CIK:        0001837607
Form:       8-K
Filed at:   2024-02-16T23:59:59+00:00
Accession:  0001558370-24-001305
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 4.02
LLM model:  deepseek-v4-flash:cloud@v2

AEON Biopharma restates Q3 2023 financials; non-cash errors increase loss by $22.7M, expects going concern doubt
--------------------------------------------------------------------------------

- Audit Committee concludes Sep 30, 2023 financials unreliable due to valuation errors in contingent consideration, convertible notes, stock comp, and derivatives.
- Non-cash corrections: Predecessor period loss increased ~$22.7M; Successor period income increased ~$6.4M; contingent consideration liability up ~$6.7M.
- Company expects additional material weaknesses and will continue reporting substantial doubt about ability to continue as going concern for 12 months.
- Merger-related reclassification errors between APIC and accumulated deficit; further revisions possible.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1837607/000155837024001305/0001558370-24-001305-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1837607/000155837024001305/aeon-20240214x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-001305

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer